• Home
  • Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Author List
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM
Publication
Blood advances
Publication ID (Profile URL)
https://researcherprofiles.org/profile/468450513
Publication Year
2024
PubMed ID
38163318
Publication Title
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 03 12; 8(5):1116-1127.